Literature DB >> 19160332

Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion.

Dina Gewaily1, Paul B Greenberg.   

Abstract

BACKGROUND: Central retinal vein occlusion (CRVO) is a common retinal vascular abnormality associated with conditions such as hypertension, diabetes, glaucoma, and a wide variety of hematologic disorders. Macular edema (ME) represents an important vision-threatening complication of CRVO. There is no proven treatment; laser photocoagulation is not effective in treating cystoid macular edema secondary to CRVO. Intravitreal steroids, such as triamcinolone acetonide, have been utilized to treat macular edema stemming from a variety of etiologies and may represent a treatment option for CRVO-ME.
OBJECTIVES: The objective of this review was to explore the effectiveness and safety of intravitreal steroids in the treatment of CRVO-ME. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 4, 2008), MEDLINE (January 1950 to November 2008) and EMBASE (January 1980 to November 2008). There were no language or date restrictions in the search for trials. The electronic databases were last searched on 5 November 2008. For all included primary studies, we used The Science Citation Index and manually reviewed reference lists to identify other possible relevant trials. We contacted researchers in the field, currently working on a randomized controlled trial (RCT) on this topic (The Standard Care versus Corticosteroid for Retinal Vein Occlusion - SCORE study), for information on additional current, past, or unpublished trials. SELECTION CRITERIA: We considered RCTs that compared intravitreal steroids of any dosage/duration to observation in the treatment of CRVO-ME for inclusion in this review. We focused on studies that included individuals of any age or gender with unilateral or bilateral disease, with a minimum of six months follow up. Secondarily we considered non-randomized studies with the same criteria for description of evidence, however we did not conduct a separate electronic search for finding all non-randomized studies. DATA COLLECTION AND ANALYSIS: We found no RCTs that met the inclusion criteria after independent and duplicate review of the search results. MAIN
RESULTS: We found no relevant RCTs and therefore performed no meta-analysis. Evidence from non-randomized studies is reported in this review. AUTHORS'
CONCLUSIONS: There is inadequate evidence for the use of intravitreal steroids for CRVO-ME due to a paucity of RCTs and well-designed observational studies on the topic; therefore, it is still an experimental procedure.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19160332      PMCID: PMC4302327          DOI: 10.1002/14651858.CD007324.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  49 in total

1.  Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion.

Authors:  Carl H Park; Glenn J Jaffe; Sharon Fekrat
Journal:  Am J Ophthalmol       Date:  2003-09       Impact factor: 5.258

2.  Intractable glaucoma following intravitreal triamcinolone in central retinal vein occlusion.

Authors:  Sushmita Kaushik; Vishali Gupta; Amod Gupta; Mangat Ram Dogra; Ramandeep Singh
Journal:  Am J Ophthalmol       Date:  2004-04       Impact factor: 5.258

3.  Intravitreal triamcinolone acetonide for the treatment of central retinal vein occlusion in young patients.

Authors:  Murat Karacorlu; Hakan Ozdemir; Serra Karacorlu
Journal:  Retina       Date:  2004-04       Impact factor: 4.256

4.  [Surgical treatment of persistent macular edema in retinal vein occlusion].

Authors:  J Nkeme; A Glacet-Bernard; K Gnikpingo; A Zourdani; G Mimoun; H Mahiddine; A Gkoritsa; A Tchamo; G Coscas; G Soubrane
Journal:  J Fr Ophtalmol       Date:  2006-09       Impact factor: 0.818

5.  Two-year results of intravitreal triamcinolone acetonide injection for the treatment of macular edema due to central retinal vein occlusion.

Authors:  Figen Batioglu; Emin Ozmert; Elif Akmese
Journal:  Ann Ophthalmol (Skokie)       Date:  2007

Review 6.  Intravitreal triamcinolone acetonide: a change in a paradigm.

Authors:  Jost B Jonas
Journal:  Ophthalmic Res       Date:  2006-06-06       Impact factor: 2.892

7.  Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report.

Authors: 
Journal:  Ophthalmology       Date:  1995-10       Impact factor: 12.079

8.  Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema.

Authors:  Baruch D Kuppermann; Mark S Blumenkranz; Julia A Haller; George A Williams; David V Weinberg; Connie Chou; Scott M Whitcup
Journal:  Arch Ophthalmol       Date:  2007-03

9.  Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion.

Authors:  Michael S Ip; Justin L Gottlieb; Alon Kahana; Ingrid U Scott; Michael M Altaweel; Barbara A Blodi; Ronald E Gangnon; Carmen A Puliafito
Journal:  Arch Ophthalmol       Date:  2004-08

10.  Macular hole and intravitreal injection of triamcinolone acetonide for macular edema due to central retinal vein occlusion.

Authors:  R Lattanzio; A Ramoni; F Scotti; U Introini
Journal:  Eur J Ophthalmol       Date:  2007 May-Jun       Impact factor: 2.597

View more
  13 in total

Review 1.  Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion.

Authors:  Tasanee Braithwaite; Afshan A Nanji; Paul B Greenberg
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

2.  Visual perceptions induced by intravitreous injections of therapeutic agents.

Authors:  S Charalampidou; J Nolan; G O Ormonde; S Beatty
Journal:  Eye (Lond)       Date:  2011-01-28       Impact factor: 3.775

Review 3.  Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion.

Authors:  Tasanee Braithwaite; Afshan A Nanji; Kristina Lindsley; Paul B Greenberg
Journal:  Cochrane Database Syst Rev       Date:  2014-05-01

4.  Efficacy of intravitreal conbercept injection on short- and long-term macular edema in branch retinal vein occlusion.

Authors:  Jing-Yi Bai; Wen-Ying Wang; Zhi-Zhi Dou; Bo-Chao Geng; Xiao-Yan Xu; Yuan-Zhang Zhu; Shan-Yao Zhao; Min Liu; Shao-You Jia; Wen-Juan Luo
Journal:  Int J Ophthalmol       Date:  2022-03-18       Impact factor: 1.779

Review 5.  Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion.

Authors:  Dina Gewaily; Karthikeyan Muthuswamy; Paul B Greenberg
Journal:  Cochrane Database Syst Rev       Date:  2015-09-09

6.  Full-thickness retinochoroidal incision in the management of central retinal vein occlusion.

Authors:  San-Ni Chen; Ya-Chi Huang
Journal:  J Ophthalmol       Date:  2015-02-05       Impact factor: 1.909

7.  Surgical results of Ahmed valve implantation combined with intravitreal triamcinolone acetonide injection for preventing choroidal detachment.

Authors:  Hua Wang; Hong Chen; Yue Qi; Ning-Li Wang
Journal:  BMC Ophthalmol       Date:  2015-01-30       Impact factor: 2.209

8.  Comparative evaluation between ranibizumab combined with laser and bevacizumab combined with laser versus laser alone for macular oedema secondary to branch retinal vein occlusion.

Authors:  Shorya Vardhan Azad; Amjad Salman; Deepankur Mahajan; Siddharth Sain; Rajvardhan Azad
Journal:  Middle East Afr J Ophthalmol       Date:  2014 Oct-Dec

Review 9.  Treatments for macular oedema following central retinal vein occlusion: systematic review.

Authors:  John A Ford; Christine Clar; Noemi Lois; Samantha Barton; Sian Thomas; Rachel Court; Deepson Shyangdan; Norman Waugh
Journal:  BMJ Open       Date:  2014-02-10       Impact factor: 2.692

10.  Bevacizumab for CRVO Associated CME: Effect of Timing and Frequency of Injections on Final Visual Outcome.

Authors:  Joseph Pikkel; Otzem Chassid; Yumna Busool; Ward Srour; Adi Sharabi-Nov; Itzchak Beiran
Journal:  J Ophthalmol       Date:  2013-12-29       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.